Sweden’s Medivir (Nasdaq: MVIR) says it will reduce activities “not critical to its development pipeline of drug candidates,” including cutting around 60 staff, as part of a cost-cutting plan.
The firm is also exploring strategic alternatives for its research stage projects and organization.
Medivir said earlier this week it would replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze